Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 16/20 | 1.00 |
| ▸ | ERBB2 | P04626 | 7/20 | 1.00 |
| ▸ | ERBB3 | P21860 | 1/20 | 0.70 |
| ▸ | DUS2 | Q9NX74 | 1/20 | 0.70 |
| ▸ | FYN | P06241 | 4/20 | 0.69 |
| ▸ | SRC | P12931 | 4/20 | 0.69 |
| ▸ | ERBB4 | Q15303 | 2/20 | 0.67 |
| ▸ | RET | P07949 | 1/20 | 0.67 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31605602 | 1.00 | EGFR (1.00) | EGFRERBB2ERBB3DUS2FYN | |
| SCHEMBL2251187 | 0.88 | EGFR (0.78) | EGFRERBB2ERBB3DUS2ERBB4 | |
| SCHEMBL2993868 | 0.88 | EGFR (1.00) | EGFRERBB2ERBB3DUS2ERBB4 | |
| SCHEMBL3240208 | 0.86 | EGFR (1.00) | EGFRERBB2FYNSRC | |
| SCHEMBL2251606 | 0.86 | EGFR (0.75) | EGFRERBB2ERBB3DUS2ERBB4 | |
| SCHEMBL2986894 | 0.86 | EGFR (1.00) | EGFRERBB2FYNSRCERBB4 | |
| Hydrochloric Acid SCHEMBL3000541 | 0.85 | EGFR (0.98) | EGFRERBB2FYNSRCERBB4 | |
| SCHEMBL27874191 | 0.85 | EGFR (0.73) | EGFRERBB2ERBB3DUS2ERBB4 | |
| SCHEMBL25649216 | 0.85 | EGFR (0.78) | EGFRERBB2ERBB3DUS2FYN | |
| SCHEMBL8580434 | 0.84 | EGFR (0.72) | EGFRERBB2ERBB4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0892789-B2 | IRREVERSIBLE INHIBITORS OF TYROSINE KINASES | WARNER LAMBERT CO (US) | 2009-11-18 | — | — | EP | claimed |
| CN-1923818-A | Irreversible inhibitors of tyrosine kinases | WARNER LAMBERT CO (US) | 2007-03-07 | — | — | CN | claimed |
| CN-1495172-A | Irreversible inhibitors of tyrosine kinases | ��ʲ | 2004-05-12 | — | — | CN | claimed |
| US-20030229051-A1 | Irreversible inhibitors of tyrosine kinases | BRIDGES ALEXANDER JAMES (US) | 2003-12-11 | — | — | US | claimed |
| CN-1370535-A | Method of inhibiting skin damage of vitamin A analog | WANER LONGBER CO (US) | 2002-09-25 | — | — | CN | claimed |
| EP-0892789-B1 | IRREVERSIBLE INHIBITORS OF TYROSINE KINASES | WARNER LAMBERT CO (US) | 2002-02-27 | — | — | EP | claimed |
| CN-1218456-A | Irreversible inhibitors of tyrosine kinases | WARNER LAMBERT CO (US) | 1999-06-02 | — | — | CN | claimed |
| EP-0892789-A1 | IRREVERSIBLE INHIBITORS OF TYROSINE KINASES | WARNER-LAMBERT COMPANY (US) | 1999-01-27 | — | — | EP | claimed |
| WO-1997038983-A1 | IRREVERSIBLE INHIBITORS OF TYROSINE KINASES | WARNER-LAMBERT COMPANY (US) | 1997-10-23 | — | — | WO | claimed |
| US-7786131-B2 | Anticancer agents; restenosis; atherosclerosis; skin disorders | WARNER-LAMBERT COMPANY (US) | 2010-08-31 | — | — | US | disclosed |
| EP-0892789-B2 | IRREVERSIBLE INHIBITORS OF TYROSINE KINASES | WARNER LAMBERT CO (US) | 2009-11-18 | — | — | EP | disclosed |
| CN-100503580-C | Irreversible inhibitors of tyrosine kinases | WARNER LAMBERT CO (US) | 2009-06-24 | — | — | CN | disclosed |
| CN-1923818-A | Irreversible inhibitors of tyrosine kinases | WARNER LAMBERT CO (US) | 2007-03-07 | — | — | CN | disclosed |
| CN-1194692-C | Method of inhibiting skin damage of vitamin A analog | WANER LONGBER CO (US) | 2005-03-30 | — | — | CN | disclosed |
| EP-1230919-A2 | Use of a composition comprising a retinoid and an erb inhibitor in the preparation of a medicament for the treatment of retinoid skin damage | WARNER-LAMBERT COMPANY (US) | 2002-08-14 | — | — | EP | disclosed |
| EP-0892789-B1 | IRREVERSIBLE INHIBITORS OF TYROSINE KINASES | WARNER LAMBERT CO (US) | 2002-02-27 | — | — | EP | disclosed |
| US-6344459-B1 | TREATING CANCER, RESTENOSIS, ATHEROSCLEROSIS, ENDOMETRIOSIS, AND PSORIASIS | WARNER-LAMBERT COMPANY | 2002-02-05 | — | — | US | disclosed |
| CN-1218456-A | Irreversible inhibitors of tyrosine kinases | WARNER LAMBERT CO (US) | 1999-06-02 | — | — | CN | disclosed |
| EP-0892789-A1 | IRREVERSIBLE INHIBITORS OF TYROSINE KINASES | WARNER-LAMBERT COMPANY (US) | 1999-01-27 | — | — | EP | disclosed |
| WO-1997038983-A1 | IRREVERSIBLE INHIBITORS OF TYROSINE KINASES | WARNER-LAMBERT COMPANY (US) | 1997-10-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030229051-A1 | Irreversible inhibitors of tyrosine kinases | ERBB2, ERBB3, LCK | EGFR 26/4885ERBB2 1/4885ERBB3 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.